| Overview |
| bsm-30030m-apc-cy7-100t |
| human CD38/APC-Cy7 |
| FCM |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Monoclonal |
| 8G6 |
| IgG1/Kappa |
| n/a |
| Affinity purified by Protein G |
| 0.01M PBS, 0.5%BSA, 0.02% Proclin300 |
| Store at 2-8°C |
| Target |
| 952.0 |
| P28907 |
| ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1; 2'-phospho-ADP-ribosyl cyclase; 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase; 2'-phospho-cyclic-ADP-ribose transferase; ADP-ribosyl cyclase 1; ADPRC 1; Cyclic ADP-ribose hydrolase 1; cADPr hydrolase 1; T10; CD38_HUMAN; I-19; NIM-R5 antigen. |
| The protein encoded by this gene is a non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes cyclic adenosine 5'-diphosphate-ribose, an intracellular calcium ion mobilizing messenger. The release of soluble protein and the ability of membrane-bound protein to become internalized indicate both extracellular and intracellular functions for the protein. This protein has an N-terminal cytoplasmic tail, a single membrane-spanning domain, and a C-terminal extracellular region with four N-glycosylation sites. Crystal structure analysis demonstrates that the functional molecule is a dimer, with the central portion containing the catalytic site. It is used as a prognostic marker for patients with chronic lymphocytic leukemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015] |
| Application Dilution |
| FCM |
10ul/10^6 cells in 100ul |